iSpecimen (NASDAQ:ISPC) Shares Down 3.7% – What’s Next?

Posted by Casey Walker on Jul 31st, 2026

Shares of iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) dropped 3.7% on Thursday . The stock traded as low as $1.83 and last traded at $1.83. 23,118 shares traded hands during mid-day trading, a decline of 78% from the average daily volume of 106,162 shares. The stock had previously closed at $1.90.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Wall Street Zen upgraded iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Report on iSpecimen

iSpecimen Stock Down 3.7%

The stock has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.03 and a beta of 1.63. The stock’s 50-day simple moving average is $2.63 and its 200 day simple moving average is $6.67.

iSpecimen (NASDAQ:ISPC – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($6.66) earnings per share for the quarter. iSpecimen had a negative return on equity of 584.65% and a negative net margin of 1,080.16%.The firm had revenue of $0.16 million for the quarter.

Institutional Investors Weigh In On iSpecimen

A hedge fund recently bought a new position in iSpecimen stock. Virtu Financial LLC acquired a new stake in iSpecimen Inc. (NASDAQ:ISPC – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned about 0.65% of iSpecimen as of its most recent filing with the SEC. 13.62% of the stock is owned by institutional investors and hedge funds.

About iSpecimen

(Get Free Report)

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.